Document:

EX-10.1

 Exhibit 10.1 

WESTFIELD FINANCIAL, INC. 

2014 OMNIBUS INCENTIVE PLAN 

LONG-TERM INCENTIVE AND RETENTION EQUITY AWARD AGREEMENT 

Westfield Financial, Inc. (the “Company”), hereby grants shares of Common Stock of the Company, $.01 par value per
share (the “Shares”), to the individual named below as the Grantee, subject to the terms and conditions set forth in this cover sheet, in the attached Employee Long Term Incentive and Retention Equity Award Agreement
(together, the “Agreement”) and in the Company’s 2014 Omnibus Incentive Plan (the “Plan”). 
 Grant
Date:                      
 Name of Grantee:
                     
 Number of Retention
Shares:              
 Maximum Number of Performance Shares:
             
 Retention Period: January 1, 2016 to December 31, 2018 

Performance Period: January 1, 2016 to December 31, 2018 

By your signature below, you agree to all of the terms and conditions described in the Agreement and in the Plan, a copy of which is
also attached. You acknowledge that you have carefully reviewed the Plan and agree that the Plan will control in the event any provision of this Agreement should appear to be inconsistent with the Plan. 

 

					
	Grantee:	 	  
	  	Date:                                     
               
		 	(Signature)	  	

  

					
	Company:	 	  
	  	Date:                                     
               
		 	(Signature)	  	

  

							
		 	Name:	 	  
	  	
				
		 	Title:	 	  
	  	

 Attachment 

This is not a share certificate or a negotiable instrument. 

  
 1 

 WESTFIELD FINANCIAL INC. 

2014 OMNIBUS INCENTIVE PLAN 

LONG-TERM INCENTIVE AND RETENTION EQUITY AWARD AGREEMENT 
  

			
	Restricted Stock	  	This grant consists of an award of time-based restricted shares, subject to the vesting conditions described below (the “Retention Shares”) and an award of performance-based restricted shares, subject to
the vesting conditions described below (the “Performance Shares”). The Retention Shares and the Performance Shares are referred to together as the “Restricted Stock.” The purchase price for the
Restricted Stock is deemed paid by your services to the Company.
		
	Transferability	  	Until the Restricted Stock is vested, it may not be transferred, assigned, pledged or hypothecated, whether by operation of law or otherwise, nor may the Restricted Stock be made subject to execution, attachment or similar
process.
		
	Number and Vesting of Retention Shares	  	 The number of Retention Shares is set forth on the cover sheet and will be equal to half the total number of shares of Common Stock that
comprise the grant of Restricted Stock. The Retention Shares are subject to time-based vesting conditions.
  

Your Retention Shares will be subject to forfeiture if your Service terminates prior to the applicable Retention Vesting Date (as set forth on Exhibit A
to this Agreement), except as provided in this Agreement.

		
	Number and Vesting of Performance Shares	  	 The Performance Shares are subject to the achievement of the Performance Factor described in Exhibit B to this Agreement. Following
the end of the Performance Period, as set forth on the cover sheet, the Committee will determine the level of achievement of the Performance Factors and will determine the number of Performance Shares in which you will vest based on such achievement
(which may be equal to all or a portion, including none, of the Maximum Number of Performance Shares, as set forth on the cover sheet).
  

Your Performance Shares will be subject to forfeiture if your Service terminates prior to the Performance Vesting Date set forth in Exhibit B to this
Agreement, except as provided in this Agreement.

		
	Evidence of Issuance	  	The issuance of the shares of Common Stock upon the grant of Restricted Stock pursuant to this Agreement will be evidenced in such a manner as the Company, in its discretion, deems appropriate, including, without limitation, book
entry, registration or issuance of one or more stock certificates, with any unvested Restricted Stock bearing the appropriate restrictions imposed by this Agreement. As your interest in the Restricted Stock vests, the recordation of the number of
Restricted Stock attributable to you will be appropriately modified if necessary.

  
 2 

			
	Vesting and Forfeiture upon Termination of Employment	  	 Death/Disability. If your Service terminates prior to the end of the Retention Period (as defined on the cover sheet) because of
your death or Disability (as defined below), then 100% of the unvested Retention Shares (as defined on the cover sheet) will vest on the effective date of your termination. If your Service terminates prior to the end of the Performance Period (as
defined on the cover sheet) because of your death or Disability (as defined below), then the Maximum Number of Performance Shares will vest on the effective date of your termination.

 
 Other Termination of Employment. If, before the end of the Retention Period, you
incur a termination of employment for any reason other than those specified above, whether voluntary or involuntary and prior to a Change in Control, your unvested Retention Shares shall be automatically forfeited upon such termination of Service
and neither the Company nor any Affiliate shall have any further obligations to you under this Agreement. If, before the end of the Performance Period, you incur a termination of employment for any reason other than those specified above, whether
voluntary or involuntary and prior to a Change in Control, your Performance Shares shall be automatically forfeited upon such termination of Service and neither the Company nor any Affiliate shall have any further obligations to you under this
Agreement.

		
	Definition of Disability	  	For purposes of this Agreement, “Disability” means, as determined by the Committee and unless otherwise provided in an applicable agreement with the Company, the Bank, or an Affiliate, your inability to
perform each of the essential duties of your position by reason of a medically determinable physical or mental impairment which is potentially permanent in character or which can be expected to last for a continuous period of not less than twelve
(12) months.
		
	Change in Control	  	 If, within twelve months following the effective time of a Change in Control (as defined in the Plan), your employment is terminated by
the Company without Cause or you voluntarily terminate employment for Good Reason (as defined below), and such termination occurs prior to the end of the Retention Period or the Performance Period, then 100% of the unvested Retention Shares and the
Maximum Number of Performance Shares, respectively, will vest on the date of your termination.
  

For purposes of this Agreement, “Cause” means, unless otherwise provided in an applicable agreement with the Company, the Bank, or an
Affiliate, your (a) personal dishonesty, (b) incompetence, (c) willful misconduct, (d) breach of fiduciary duties involving personal profit, (e) intentional failure to perform stated duties, or (f) willful violation of any law, rule, or regulation
(other than traffic violations or similar offenses) or final cease-and-desist order. Any determination by the Committee whether an event constituting Cause shall have occurred shall be final, binding, and
conclusive.

  
 3 

			
		  	For purposes of this Agreement, “Good Reason” means, unless otherwise provided in an applicable agreement with the Company, the Bank, or an Affiliate, the occurrence of either of the following events,
without your express written consent: (A) a material diminution in your authority, duties, or responsibilities; or (B) a change in your principal place of employment to a place that is not the principal executive office of the Company, or a
relocation of the Company’s principal executive office to a location that is both more than twenty-five (25) miles away from your principal residence and more than twenty-five (25) miles away from the location of the Company’s principal
executive office at the time of this Agreement. Notwithstanding the foregoing, a resignation will not be considered to have been on account of Good Reason unless: (1) you provide the Company not less than 30 days’ advance notice in writing
within 90 days of the initial occurrence of the condition that is the basis for such Good Reason and the Company does not correct the condition in the 30-day period; and (2) you resign by no later than 60 days after the Company’s time period
for correcting the condition has expired.
		
	Leaves of Absence	  	 For purposes of this Agreement, your Service does not terminate when you go on a bona fide employee leave of absence that was approved by
the Company, the Bank, or any Affiliate in writing, if the terms of the leave provide for continued Service crediting, or when continued Service crediting is required by applicable law. However, your Service will be treated as terminating ninety
(90) days after you went on employee leave, unless your right to return to active work is guaranteed by law or by a contract. Your Service terminates in any event when the approved leave ends unless you immediately return to active employee
work.
  
 The Committee determines, in its sole discretion, which leaves count for this
purpose and when your Service terminates for all purposes under the Plan.

		
	Withholding Taxes	  	You agree, as a condition of this Grant, that you will make acceptable arrangements to pay any withholding or other taxes that may be due as a result of the payment of dividends or the vesting of Stock acquired under this Grant.
In the event that the Company, the Bank, or any Affiliate determines that any federal, state, local, or foreign tax or withholding payment is required relating to the payment of dividends or the vesting of shares arising from this Grant, the
Company, the Bank, or any Affiliate shall have the right to require such payments from you, or withhold such amounts from other payments due to you from the Company, the Bank, or any Affiliate. To satisfy this withholding obligation, the Company may
provide you with the opportunity, in its discretion, to have the Company withhold shares of Stock otherwise issuable to you or by delivering to the Company shares of Stock already owned by you. If the Company provides you with the foregoing
opportunity and you fail to make an election to do either, the Company

  
 4 

			
		  	may determine which method to use, including by withholding shares of Stock otherwise issuable to you. The shares of Stock so delivered or withheld must have an aggregate Fair Market Value equal to the withholding obligation and
may not be subject to any repurchase, forfeiture, unfulfilled vesting, or other similar requirements.
		
	Retention Rights	  	This Agreement does not give you the right to be retained by the Company (or any Affiliates) in any capacity. The Company (and any Affiliate) reserves the right to terminate your Service at any time and for any reason.
		
	Stockholder Rights	  	You have the right to vote the Retention Shares and to receive any dividends declared or paid on such Retention Shares. Any distributions you receive as a result of any stock split, dividend, combination of Shares or other
similar transaction will be deemed to be a part of the Retention Shares and subject to the same conditions and restrictions applicable thereto. Except as described in the Plan, no adjustments are made for dividends or other rights if the applicable
record date occurs before an appropriate book entry is made (or your share certificate is issued). The Company may in its sole discretion require any dividends paid on unvested Retention Shares to be reinvested in Shares, which the Company may in
its sole discretion deem to be a part of the Retention Shares and subject to the same conditions and restrictions applicable to the Retention Shares. You do not have any of the rights of a stockholder with respect to the Performance Shares unless
and until any Performance Shares in which you vest have been delivered to you.
		
	Forfeiture of Rights	  	If you should take actions in violation or breach of or in conflict with (i) any employment agreement, (ii) any non-competition agreement, (iii) any agreement prohibiting solicitation of employees or clients of the Company, the
Bank, or any Affiliate, (iv) any confidentiality obligation with respect to the Company, the Bank, or any Affiliate, (v) any Company or Bank policy or procedure, (vi) any other agreement, or (vii) any other obligation between you and the Company,
the Bank, or any Affiliate, the Company has the right to cause an immediate forfeiture of your unvested Restricted Stock, and with respect to those shares of Restricted Stock vesting during the period commencing twelve (12) months prior to your
termination of Service with the Company due to taking actions in violation or breach of or in conflict with the aforementioned agreements, policies, or procedures, the right to cause a forfeiture of those vested shares of Stock.
		
	Recoupment	  	 This Grant is subject to mandatory repayment by you to the Company to the extent you are or in the future become subject to (i) any
Company or Bank “clawback” or recoupment policy or (ii) any law, rule, or regulation that requires the repayment by you to the Company of compensation paid by the Company to you in the event that you fail to comply with, or violate, the
terms or requirements of such policy or law, rule, or regulation.
  
 If the Company is
required to prepare an accounting restatement due to

  
 5 

			
		  	the material noncompliance of the Company, as a result of misconduct, with any financial reporting requirement under the securities laws and you knowingly engaged in the misconduct, were grossly negligent in engaging in the
misconduct, knowingly failed to prevent the misconduct, or were grossly negligent in failing to prevent the misconduct, you will reimburse the Company the amount of any payment in settlement of this Grant earned or accrued during the twelve
(12)-month period following the first public issuance or filing with the Securities and Exchange Commission (whichever first occurred) of the financial document that contained such material noncompliance.
		
	Adjustments	  	In the event of a stock split, a dividend or a similar change in the Shares, the number of Shares covered by this grant may be adjusted (and rounded down to the nearest whole number) pursuant to the Plan.
		
	Legends	  	 All share certificates representing the Stock issued in connection with this Grant shall, where applicable, have endorsed thereon the
following legend:
  
 “THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO
CERTAIN RESTRICTIONS ON TRANSFER SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE REGISTERED HOLDER, OR HIS OR HER PREDECESSOR IN INTEREST. A COPY OF SUCH AGREEMENT IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY AND WILL BE FURNISHED UPON
WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY BY THE HOLDER OF RECORD OF THE SHARES REPRESENTED BY THIS CERTIFICATE.”

		
	Applicable Law	  	This Agreement will be interpreted and enforced under the laws of the Commonwealth of Massachusetts, other than any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this
Agreement to the substantive law of another jurisdiction.
		
	Other Agreements	  	You agree, as a condition of this grant, that you will execute such documents as necessary to become a party to any stockholder agreement or voting trust as the Company may require.
		
	Data Privacy	  	 To administer the Plan, the Company may process personal data about you. Such data includes, but is not limited to the information
provided in this Agreement and any changes thereto, other appropriate personal and financial data about you such as home address and business addresses and other contact information, and any other information that might be deemed appropriate by the
Company to facilitate the administration of the Plan.
  
 By accepting this grant, you
give explicit consent to the Company to process any such personal data. You also give explicit consent to the Company to transfer any such personal data outside the country in which you work, including, with respect to non-U.S. resident
grantees,

  
 6 

			
		  	to the United States, to transferees who will include the Company and other persons who are designated by the Company to administer the Plan.
		
	Consent to Electronic Delivery	  	The Company may choose to deliver certain statutory materials relating to the Plan in electronic form. By accepting this grant, you agree that the Company may deliver the Plan prospectus and the Company’s annual report to
you in an electronic format. If at any time you would prefer to receive paper copies of these documents, as you are entitled to, the Company would be pleased to provide copies. Please contact the Secretary of the Company to request paper copies of
these documents.
		
	The Plan	  	 The text of the Plan is incorporated in this Agreement by reference.

 
 Certain capitalized terms used in this Agreement are defined in the Plan, and have
the meaning set forth in the Plan.
  
 This Agreement and the Plan constitute the
entire understanding between you and the Company regarding this grant of Restricted Stock. Any prior agreements, commitments or negotiations concerning this grant are superseded.

		
	Code Section 409A	  	The Grant is intended to be exempt from, or to comply with, Code Section 409A to the extent subject thereto, and, accordingly, to the maximum extent permitted, this Agreement will be interpreted and administered to be in
compliance with Code Section 409A. Notwithstanding anything to the contrary in the Plan or this Agreement, neither the Company, the Bank, their Affiliates, the Board, nor the Committee will have any obligation to take any action to prevent the
assessment of any excise tax or penalty on you under Code Section 409A and neither the Company, the Bank, their Affiliates, the Board, nor the Committee will have any liability to you for such tax or penalty.

 By signing this Agreement, you agree to all of the terms and 

conditions described in this Agreement and in the Plan. 

  
 7 

 EXHIBIT A 

LONG-TERM INCENTIVE AND RETENTION EQUITY AWARD AGREEMENT 

NUMBER AND VESTING OF RETENTION SHARES 

The Retention Shares are subject to the Time-Based Vesting Requirements set forth below. 

Time-Based Vesting Requirements: 
 Except as
otherwise described in the Agreement, your Retention Shares will vest as follows: 
  

					
	Retention Vesting Date	  	Vesting Percentage	 
	 December 31, 2016
	  	 	33	% 
	 December 31, 2017
	  	 	33	% 
	 December 31, 2018
	  	 	34	% 

 The resulting aggregate number of vested Retention Shares will be rounded down to the nearest whole number as to each
Retention Vesting Date, and you cannot vest in more than the number of Retention Shares set forth on the cover sheet. 

  
 8 

 EXHIBIT B 

LONG-TERM INCENTIVE AND RETENTION EQUITY AWARD AGREEMENT 

NUMBER AND VESTING OF PERFORMANCE SHARES 

The Performance Shares are subject to both the Performance-Based Vesting Requirements and Time-Based Vesting Requirements set forth below. 

Performance-Based Vesting Requirements: 
 The
Committee will determine the number of Performance Shares in which you will vest based on the Company’s achievement of Return on Equity (“ROE”) goals during the period of time beginning on January 1, 2016 and ending
on December 31, 2018 (the “Performance Period”), subject to your continued Service with the Company or an Affiliate through the end of the Performance Period. Following the end of the Performance Period, but no later
than March 15, 2019, the Committee will calculate the ROE for the Company for the Performance Period based on data available to the public. 
 The
Committee will calculate the number of Performance Shares in which you vest by multiplying the Maximum Number of Performance Shares (as set forth on the cover sheet) by the ROE Performance Factor determined under the following table: 

 

									
	 	  	Return on Equity for the
Performance Period	 	 	ROE Performance Factor
(%)	 
	 Less than Threshold
	  	 	< 5.85	% 	 	 	0	% 
	 Threshold
	  	 	5.85	% 	 	 	50	% 
	 Target
	  	 	6.32	% 	 	 	100	% 

 If the ROE for the Performance Period falls between threshold and target performance levels, the ROE Performance Factor will
be interpolated on a linear slope. 
 Notwithstanding anything to the contrary in the Agreement or this Exhibit B, no Performance Shares will vest if
the threshold ROE is not attained. Additionally, in no event may you vest in a number of Performance Shares greater than the Maximum Number of Performance Shares as set forth on the cover sheet of the Agreement. 

  
 9EX-10.1

 Exhibit 10.1 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 AMENDED AND RESTATED NANTOMICS EXCLUSIVE RESELLER AGREEMENT 

This Amended and Restated NantOmics Exclusive Reseller Agreement (this “Agreement”) is made as of May 9, 2016, with an
effective date as of June 19, 2015 (the “Effective Date”), by and between NantOmics, LLC, a Delaware limited liability company (“NantOmics”), and Nant Health, LLC, a Delaware limited liability company
(“NantHealth”). NantOmics and NantHealth are sometimes referred to herein as a “Party” and collectively as the “Parties.” 

RECITALS 
 WHEREAS,
NantOmics has developed and makes available certain genomic and proteomic analysis and bioinformatics services; 
 WHEREAS, NantHealth and
NantOmics are parties to that certain NantOmics Exclusive Reseller Agreement (the “Original Agreement”), effective as of June 19, 2015, under which NantHealth obtained the right to market and resell such services on an
exclusive basis in the Commercial Field of Use (defined below); 
 WHEREAS, NantHealth and NantOmics wish to amend and restate the Original
Agreement with the terms of this Agreement to clarify certain terms of the Original Agreement. 
 NOW, THEREFORE, for good and valuable
consideration, including the mutual covenants and conditions herein contained, the Parties do hereby (a) amend, restate and replace the Original Agreement in its entirety and (b) otherwise agree as follows: 

AGREEMENT 
 1. Definitions.
Capitalized terms that are used but not otherwise defined in this Agreement shall have the meanings set forth below: 

“Affiliate” means, with respect to a Person, any other Person that directly or indirectly, through one or more
intermediaries, Controls, is Controlled by, or is under common Control with, such Person. For purposes of this Agreement, (i) NantHealth and its Subsidiaries shall not be deemed to be Affiliates of NantOmics and (ii) NantOmics and its
Affiliates shall not be deemed to be Affiliates of NantHealth. 
 “Claim” means any claim, action, suit, or proceeding.

 “Commercial Field of Use” means the marketing, sale and provision of Omics Services on a fee basis to Institutional
Customers, in each case, for use in connection with the information provided to an Institutional Customer. For the avoidance of doubt, the “Commercial Field of Use” does not include Omics Services provided primarily for research or
educational purposes or for consumer applications or primarily for the discovery, development, evaluation, trial, analysis or regulatory approval of any pharmaceutical or therapeutic product or treatment, or any companion diagnostic, biomarker,
neoantigen or neoepitope. 
 “Confidential Information” means non-public information of a Disclosing Party or its
Affiliates, including (a) any trade secrets and any information relating to the Disclosing Party’s current and planned products and services, technology, source code, techniques, know-how, research, engineering, designs, finances,
accounts, procurement requirements, manufacturing, customer lists, business forecasts, and marketing; (b) any information disclosed in writing that is clearly marked “confidential” or with a similar proprietary notice at the time of
disclosure; (c) any information disclosed verbally that is identified as “confidential” or similarly at the time of disclosure, or which, by its nature, a reasonable person would consider confidential; (d) the terms and
conditions of this Agreement; and (e) Omics Data. 

  

			
	 Amended and Restated NantOmics Exclusive Reseller Agreement

CONFIDENTIAL
	 	 Page 1 of 20

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 “Control” means the direct or indirect power to direct or cause the
direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. 

“Customer Agreement” means an agreement that is accepted and agreed to by an Institutional Customer for the provision Omics
Services sold by NantHealth or its Subsidiary under this Agreement. 
 “Institutional Customer” means an insurer, payor,
self-insured health plan or healthcare provider that pays for, or agrees to pay for, Omics Services. For the avoidance of doubt, “Institutional Customers” do not include research, academic or educational institutions, pharmaceutical or
biotechnology companies or individual patients or consumers. 
 “Law” means any statute, law, ordinance, regulation, rule,
code, order, constitution, treaty, common law, judgment, decree, or other requirement or rule of any federal, state, local, or foreign government or political subdivision thereof, or any arbitrator, court, or tribunal of competent jurisdiction. 

“License Agreement” means that certain License Agreement between NantHealth and NantOmics of even date herewith, in form
attached hereto as Exhibit A. 
 “Loss” means all losses, damages, liabilities, deficiencies, judgments,
settlements, interest, awards, penalties, fines, costs, or expenses of whatever kind, including reasonable attorneys’ fees, the costs of enforcing any right to indemnification hereunder, and the cost of pursuing any insurance providers. 

“NantOmics Marks” means the trade names, trade dress, trademarks, service marks, logos, brand names and other identifiers of
NantOmics or otherwise used in connection with any Omics Services, including any applications, registrations, and renewals thereof. 

“Omics Data” means [***]. 

“Omics Platform” means the hardware, software, systems, tools, database processes, reporting methodology, testing procedures
and other technology utilized by or for NantOmics in the operation or provision of Omics Services. 
 “Omics Report” means
the final, clinical report issued by NantOmics via the Omics Services hereunder for delivery to the applicable requisitioning physician. 

“Omics Services” means whole genome sequencing, whole exome sequencing, RNA-Seq and quantitative proteomics, and
computational and data management and bioinformatics services, made commercially available by NantOmics to NantHealth for NantHealth to resell to Institutional Customers during the Term in accordance with this Agreement. 

“Other Services” means consulting and other professional services that may be provided by or on behalf of NantOmics to
NantHealth, its Subsidiaries or an Institutional Customer from time to time in connection with this Agreement. 
 “Person”
means any natural person, corporation, limited liability company, general partnership, limited partnership, trust, proprietorship, joint venture, business organization, or government, political subdivision, agency or instrumentality. 

  

			
	 Amended and Restated NantOmics Exclusive Reseller Agreement

CONFIDENTIAL
	 	 Page 2 of 20

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 “Representatives” means a with respect to a Party or its Affiliates, each of
their respective employees, officers, directors, partners, shareholders, agents, attorneys, and third-party advisors. 

“Services” means the Omics Services and Other Services, collectively. 

“Subsidiary” means, with respect to a Person, any other Person that is directly or indirectly, through one or more
intermediaries, Controlled by such Person. 
 “Term” has the meaning set forth in Section 13 hereof. 

“Territory” means the entire world. 
  

	2.	Appointment as Reseller. 

 2.1 Appointment. Subject to the restrictions and
obligations set forth in this Agreement, NantOmics hereby appoints NantHealth, during the Term, as an exclusive reseller of the Omics Services in and for the Commercial Field of Use, with the exclusive right to market and sell Omics Services in the
Territory to and for Institutional Customers in and for the Commercial Field of Use. 
 2.2 Exclusivity. The rights granted to
NantHealth under Section 2.1 are exclusive. Accordingly, during the Term and except to the extent otherwise agreed by the Parties on a case-by-case basis: (i) NantOmics will not provide or otherwise make available Omics Services to
other Persons in or for the Commercial Field of Use and will not authorize or grant any other Person the right to market or sell Omics Services in or for the Commercial Field of Use and (ii) the Omics Services will be the only whole genome
sequencing, whole exome sequencing, RNA-Seq and quantitative proteomics, and computational and data management and bioinformatics services marketed, sold or otherwise made available by NantHealth and its Subsidiaries. For the avoidance of doubt, the
foregoing exclusivity does not apply, and NantOmics reserves the right to offer and make Omics Services available, outside the Commercial Field of Use. 

2.3 Customer Engagement, Billing and Order Processing. NantHealth will (i) provide and manage, in its reasonable discretion,
relationships relating to the Omics Services, including patient engagement, communication with Institutional Customers and, in coordination with NantOmics, order processing and tissue and blood sample collection and (ii) manage billing,
payments, billing inquiry, collections and other transaction related processes for the Omics Services via direct interaction with Institutional Customers (which may include the delivery of general reports to Institutional Customers regarding Omics
Services provided to/for such Institutional Agreements) (collectively, “Omics Transactional Activities”). 
 2.4 Order
Fulfillment Process. The Parties will work together in good faith to develop and implement mutually agreeable processes and systems for communicating and processing Omics Service orders and the delivery of Omics Service reports and results,
including access by NantOmics to NantHealth CRM solutions used for order tracking and access and/or integration with laboratory information management systems utilized by NantOmics. 

2.5 Branding. The Omics Services (including sample collection kits) will be branded under the NantOmics Marks and/or other branding
selected by NantOmics; provided that NantHealth shall be identified as the reseller of such services in a mutually agreeable manner. 

  

			
	 Amended and Restated NantOmics Exclusive Reseller Agreement

CONFIDENTIAL
	 	 Page 3 of 20

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 2.6 Marketing and Promotion. 

(a) The Parties will work together in good faith to develop marketing strategies, plans and materials to be used for the promotion and sale of
Omics Services under this Agreement and NantHealth agrees that it will only use marketing materials that have been mutually agreed by the Parties. Further, the Parties shall cooperate in good faith to coordinate marketing and sales activities,
including in the development of sales proposals and forecasts and in capacity planning for Omics Services. 
 (b) NantOmics will provide
commercially reasonable sales and marketing support to NantHealth regarding the Omics Services, which may include: (i) providing commercially reasonable training to NantHealth’s sales personnel; (ii) participating in sales meetings
with NantHealth’s sales personnel; and (iii) reasonably cooperating with NantHealth in responding to requests for proposals or related sales discussions regarding the Omics Services and requests regarding specific requirements in Customer
Agreements that relate to the Omics Services. 
 (c) NantHealth shall: (i) use commercially reasonable efforts to market and actively
promote the Omics Services in a professional manner that brings credit to NantOmics and enhances the reputation of NantOmics and the Omics Services; (ii) refrain from making claims or representations concerning Omics Services, other than as set
forth in the mutually agreed upon marketing materials; and (iii) consult with NantOmics regarding any marketing or trade practice that might affect the good name, trademarks, goodwill or reputation of NantOmics or the Omics Services. 

2.7 Provision and Quality of Services. NantOmics will use its commercial reasonable efforts to provide the Services in a timely,
skillful, professional and workmanlike manner by qualified personnel exercising care, skill and diligence consistent with industry standards, and in accordance with the terms and conditions of this Agreement. 

2.8 Customer Agreements. NantHealth will only exercise its rights under Section 2.1 if: (i) NantHealth obtains
appropriate authorization and the informed consent from the applicable patient under an informed consent document provided by or otherwise approved by NantOmics (which informed consent document shall provide NantOmics with rights to Omics Data as
contemplated in this Agreement) and (ii) with respect to any Institutional Customer, such Intuitional Customer executes a Customer Agreement with terms and conditions no less protective of NantOmics and its service providers than the applicable
terms and conditions related to NantHealth’s own products and services and, with respect to the Omics Services, reasonable warranty disclaimers and liability limits for services of this type and rights to Omics Data as contemplated in this
Agreement. 
 2.9 Subsidiaries. NantHealth may authorize its Subsidiaries to exercise the rights granted to NantHealth under
Section 2.1, provided that such Subsidiaries agree to comply with the terms and conditions of this Agreement to the same extent that they apply to NantHealth. NantHealth shall be responsible for the acts and omissions of such
Subsidiaries which, for purposes of this Agreement, shall be deemed to be the acts and omissions of NantHealth. 
 2.10 Personnel.
Each Party will use a reasonably adequate number of qualified personnel with suitable training, education, experience and skill to enable such Party to perform under this Agreement. The Parties agree to use their reasonable efforts to promptly
resolve any good faith complaints regarding any of the other Party’s personnel, or otherwise concerning the value or efficacy of any Services or other functions performed by or on behalf of a Party in connection with this Agreement. 

2.11 Other Services. The Parties may agree, from time to time, for NantOmics to provide Other Services to NantHealth or an
Institutional Customer, in which case the Parties shall discuss in good faith and mutually agree upon the applicable rates for such Services. 

  

			
	 Amended and Restated NantOmics Exclusive Reseller Agreement

CONFIDENTIAL
	 	 Page 4 of 20

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

	3.	Revenue Share and Payment Terms. 

 3.1 Revenue Share. Unless otherwise
agreed by the Parties on a case-by-case basis, (i) NantHealth shall pay to NantOmics [***] and (ii) with respect to any Other Service provided by NantOmics, NantOmics may invoice for such Other Services on a monthly basis and such invoices
shall be due and payable within 45 days of receipt[***]. Subject to the foregoing and any restrictions expressly set forth in this Agreement or as may be separately agreed in writing by the Parties, NantHealth will have the right, in its sole
discretion, to determine the fees charged to Institutional Customers for the Omics Services resold pursuant to the Agreement. 
 [***] 

3.2 Annual Minimum. NantHealth agrees to pay NantOmics a non-cancellable annual minimum in fees in the amount of (a) $2,000,000
for each calendar year during the Initial Term beginning with and for the 2016 calendar year (i.e., $2 million for each of the 2016-2020 calendar years), (b) $25,000,000 for each calendar year during the Initial Exclusive Renewal Term
(i.e., $25 million for each of the 2021-2023 calendar years) and (c) $50,000,000 for each calendar year during the Additional Exclusive Renewal Terms (i.e., $50 million for each of the 2024-2029 calendar years) (the
“Annual Minimum”). The Annual Minimum shall be pro-rated on a per day basis if this Agreement is terminated on a date other than December 31 (i.e., ($2,000,000, $25,000,000 or $50,000,000 as applicable ÷ total
number of days in such calendar year) multiplied by the number of days that have occurred up to the date of termination). If, at the end of any calendar year or, if applicable, the termination date, the total fees paid and payable to NantOmics for
such calendar year are less than the Annual Minimum, NantHealth shall pay to NantOmics the difference between the amounts paid and payable and the Annual Minimum (the “True-up Payment”). The True-up Payment shall be due and payable
to NantOmics within forty-five (45) days after the end of such calendar year or, if applicable, the termination date. 
 3.3
Expenses. Unless otherwise expressly set forth in this Agreement, each Party will bear all of its own costs and expenses incurred in connection with this Agreement or its performance hereunder, including any development costs, sales and
marketing costs, and support costs. 
 3.4 Taxes. All fees for the Services are exclusive of any taxes, duties or other similar
governmental charges (collectively, “Taxes”). If NantOmics is required by law to collect any Taxes for the provision or supply of any Services hereunder, then NantHealth will pay such Taxes or present an exemption certificate
acceptable to the taxation authorities, provided that such Taxes are billed as a separate item on each invoice. 
 3.5 Records and
Audits. NantHealth shall keep accurate records (together with supporting documentation) of Services sold pursuant to this Agreement, appropriate to determine the amount of fees and other monies due to NantOmics hereunder. Such records shall be
retained for at least two (2) years following the end of the Term. Upon at least thirty (30) days prior written notice to NantHealth, NantOmics will be entitled to retain, at its own expense, an independent certified public accounting firm
reasonably acceptable to Nant Health (the “Auditor”), solely for the purpose of auditing those records (which shall not include access or examination of any systems) that are reasonably necessary to determine NantHealth’s
compliance with its payment obligations under this Agreement. Prior to any audit, the Auditor will be required to sign a confidentiality and/or non-disclosure agreement reasonably acceptable to NantHealth, and the results of the audit and all
information reviewed during such audit will be deemed the NantHealth’s Confidential Information. Such audit shall be conducted in accordance with generally accepted auditing standards, during NantHealth’s customary business hours, and
according to its 

  

			
	 Amended and Restated NantOmics Exclusive Reseller Agreement

CONFIDENTIAL
	 	 Page 5 of 20

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
customary office policies and procedures. NantOmics shall be entitled to one audit per calendar year during the Term and during the two (2) years thereafter. Upon the conclusion of an audit,
the period covered during such an audit may not be reexamined in any subsequent audit. If an audit discloses that NantHealth has underpaid NantOmics an amount that is more than five percent (5%) of the amount actually due under this Agreement
during any 6 month period, then NantHealth shall pay all reasonable expenses of the Auditor directly incurred by NantOmics Party for such audit in addition to the underpaid amount disclosed through such audit and due under this Agreement. 

3.6 License. In addition to the fees payable to NantOmics under this Agreement, in further consideration of the rights granted to
NantHealth hereunder, NantHealth has entered into the License Agreement with NantOmics as of the Effective Date. 
  

	4.1	Licenses and Intellectual Property Ownership. 

 4.1 Marketing Materials
License. Subject to the terms and conditions of this Agreement, NantOmics hereby grants to NantHealth a non-exclusive, non-transferable (except in accordance with Section 16.4), sublicensable (solely to NantHealth Subsidiaries),
worldwide right and license to use, reproduce and distribute any artwork or other marketing materials provided by NantOmics for inclusion in the marketing materials used by NantHealth for the Omics Services hereunder, provided that NantHealth must
receive the prior approval of such marketing materials prior to distributing any such marketing materials (which approval will not to be unreasonably withheld). 

4.2 Trademarks. 
 (a)
Subject to the terms and conditions of this Agreement, NantOmics hereby grants to NantHealth and its Subsidiaries a non-exclusive, non-transferable (except in accordance with Section 16.4) right and license to use the NantOmics Marks in
connection with the marketing, sale and provision of Omics Services hereunder and to otherwise fulfill the terms of this Agreement. 
 (b)
NantHealth’s and its Subsidiaries’ use of the NantOmics Marks must be in accordance with the NantOmics’ trademark use guidelines and instructions, if any, furnished in writing from time to time. NantOmics will give NantHealth written
notice of any changes to such specifications or guidelines, and will give NantHealth a reasonable time to modify its use of the NantOmics Marks to comply therewith. 

(c) All goodwill in and to the NantOmics Marks will inure solely to the benefit of NantOmics. 

4.3 Omics Reports. Subject to the terms and conditions of this Agreement, NantOmics hereby grants to NantHealth a non-exclusive, non-transferable (except in accordance with Section 16.4), right and license to distribute the Omics Reports solely to the applicable requisitioning physicians. 

4.4 Omics Data. Subject to the terms and conditions of this Agreement, NantOmics hereby grants to NantHealth a non-exclusive,
non-transferable (except in accordance with Section 16.4), right and license to use Omics Data collected by or for NantHealth as reasonably necessary to perform Omics Transactional Activities. 

4.5 Restrictions. NantHealth agrees that it will not, and will not permit others to: (a) reverse engineer, disassemble, decompile,
decode, modify or adapt any aspect of the technology platform used by NantOmics to provide the NantOmics Services or otherwise attempt to derive or gain access to the source code or algorithms thereof, in whole or in part; (b) remove, obscure
or alter from any NantOmics 

  

			
	 Amended and Restated NantOmics Exclusive Reseller Agreement

CONFIDENTIAL
	 	 Page 6 of 20

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
marketing materials or Omics Service reports any titles, trademarks, or copyright, patent or other proprietary or restrictive legends or notices, or any end user warning or advisory, affixed to
or contained therein or thereon; (c) release to a third party the results of any evaluation or testing of any Omics Services without NantOmics prior written approval; (d) otherwise market or sell any Omics Service or use any NantOmics
Marks or NantOmics marketing materials except as expressly set forth this Agreement or otherwise agreed in writing. 
 4.6 Ownership,
Reservation of Rights. Other than the express license rights granted by NantOmics in Sections 4.1 through 4.4 above, (a) NantOmics and its licensors reserve, retain and shall own all right, title, and interest (including intellectual
property rights) in and to the Omics Services, Omics Platform, NantOmics Marks, NantOmics marketing materials, Omics Reports, Omics Data and all other data, information, discoveries and inventions (including any improvements modifications or
derivative works of any of the foregoing) created by either party, alone or with others, in connection with the foregoing or this Agreement (collectively, the “Omics Materials”) and (b) neither NantHealth nor any third party:
(i) has or will have, acquire or claim any right, title, or interest in or to any of the Omics Materials; or (ii) has or will have any right or license to, and shall not, use any of the Omics Materials. For the avoidance of doubt, and
without limitation of the foregoing, the Omics Materials constitute the Confidential Information of NantOmics and shall include any and all companion diagnostic, biomarker, neoantigen, neoepitope and other discoveries and inventions arising from the
Omics Services, Omics Reports and/or Omics Data. NantHealth and its Affiliates agree to assign and do hereby assign any right, title or interest it may have in and to the Omics Materials to NantOmics. NantHealth and its Affiliates covenant that they
will not take any action inconsistent with NantOmic’s or its licensors’ ownership and interests set forth in this Section 4.6, or assist any Person in doing the same, including, for the avoidance of doubt, asserting any claim
or suit that the Omics Materials (or any use thereof or operation of NantOmic’s business) infringes any intellectual property right owned or controlled by NantHealth or its Affiliates. In no event will any transaction contemplated by this
Agreement be construed as a sale or assignment of NantOmics’ intellectual property. Furthermore and for the avoidance of doubt, NantOmics expressly reserves, and NantHealth may not exercise, any and all rights with respect to the Omics Services
outside the Commercial Field of Use. 
  

	5.	Other Covenants. 

 5.1 Insurance. During the Term, at such Party’s
expense, each Party will maintain policies of insurance with insurance companies having a financial strength rating no lower than “A-” and a size category not lower than “XII” as rated by the A.M. Best Company, and in amounts
which are reasonable and prudent in light of such Party’s business, potential liabilities to the other Party hereunder, and other relevant factors, including the following: (i) Commercial General Liability insurance with limits not less
than One Million U.S. Dollars ($1,000,000) combined single limit per occurrence and Two Million U.S. Dollars ($2,000,000) aggregate for products, completed operations, personal injury (including death) and property damage arising out of this
Agreement; (ii) Errors and Omissions insurance with limits of at least Five Million U.S. Dollars ($5,000,000) per occurrence and in the aggregate; and (iii) Workers’ Compensation insurance with applicable statutory limits. The
policies must contain no exclusions for sole proprietors, executive officers, partners or members and must have waivers of subrogation. 

5.2 Subcontractors. NantOmics may subcontract its obligations under this Agreement to a third party. NantOmics will remain responsible
to NantHealth for any performance of its obligations hereunder notwithstanding the permitted engagement of any such third party. 

  

			
	 Amended and Restated NantOmics Exclusive Reseller Agreement

CONFIDENTIAL
	 	 Page 7 of 20

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 5.3 Further Assurances. Each Party will, upon the reasonable request of the other
Party and at the requesting Party’s sole cost and expense, promptly execute such documents and perform such acts as may be necessary to give full effect to the terms of this Agreement. 

5.4 Compliance with Laws. Each Party will comply with all applicable Laws, governmental requirements, and industry standards, including
those with respect to privacy, data protection, portability, or accountability, applicable to such Party or its personnel with respect to the Omics Services and the performance of its obligations and exercise of its rights under this Agreement.
Neither Party will, nor permit any third parties to, export, re-export, or release, directly or indirectly, any Controlled Technology to any country or jurisdiction to which the export, re-export, or release of any Controlled Technology (a) is
prohibited by applicable Law or (b) without first completing all required undertakings (including obtaining any necessary export license or other governmental approval). As used herein, “Controlled Technology” means any
software, documentation, technology, or other technical data, or any products that include or use any of the foregoing, of which the export, re-export, or release to certain jurisdictions or countries is prohibited or requires an export license or
other governmental approval under any Law, including the U.S. Export Administration Act and its associated regulations. 
  

	6.	Force Majeure. 

 6.1 Force Majeure. Neither Party will be liable or
responsible to the other Party, nor be deemed to have defaulted under or breached this Agreement, for any failure or delay in fulfilling or performing any term of this Agreement, when and to the extent such failure or delay is caused by
(a) acts of God; (b) flood, fire, or explosion; (c) war, terrorism, invasion, riot, or other civil unrest; or (d) embargoes or blockades in effect on or after the Effective Date (each of the foregoing, a “Force Majeure
Event”); 
 6.2 Obligations. Section 6.1 and Section 14.3 will only apply to the extent (a) the
Force Majeure Event is outside the reasonable control of the affected Party and is not due to the affected Party’s fault or negligence; (b) the affected Party provides notice of the Force Majeure Event to the other Party, stating the
period of time the occurrence is expected to continue; and (c) the affected Party uses diligent efforts to end the failure or delay and minimize the effects of such Force Majeure Event. 

 

	7.	Regulatory Matters. 

 7.1 Privacy and Security Matters. The Parties agrees
that protected health information exchanged in connection with this Agreement shall be governed by that certain Bilateral Business Associate Agreement executed by the Parties (“BAA”). 

7.2 Regulation. 
 (a) If
and to the extent any Omics Service is subject to regulation by the FDA or other governmental authority, NantOmics shall fulfill, and NantHealth shall provide reasonable assistance and cooperation so that NantOmics can fulfill, all corresponding
regulatory requirements, including compliance with all applicable Laws related to premarket clearance or approval, marketing, sale and distribution of the Omics Service (and upon NantHealth’s request, NantOmics will provide NantHealth with any
such clearance or approval documentation to support the marketing of the Omics Service). 
 (b) Unless expressly agreed by NantOmics in
writing on a case-by-case basis, NantHealth will not seek any licenses, permits or approvals or make any determinations that may result in imposition of any obligations or limitations on NantOmics with respect to the regulatory status of any of
Omics Service. 

  

			
	 Amended and Restated NantOmics Exclusive Reseller Agreement

CONFIDENTIAL
	 	 Page 8 of 20

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 (c) If NantOmics decides to seek, or permits NantHealth to seek, any licenses, permits, or
approvals or to take any action that may result in any Omics Service being deemed regulated by the FDA or that may otherwise materially impact the regulatory status of any Omics Offering, then NantOmics will inform NantHealth and the Parties will
work together to minimize the effect of such regulation, obligation or limitation, to the extent reasonably practicable. 
 7.3 Omnibus
Reconciliation Act of 1980. As applicable under the Omnibus Reconciliation Act of 1980, until the expiration of four (4) years after the furnishing of Services pursuant to this Agreement, each Party will, upon receipt of written request,
and if then requested to make such information available under the then-existing Law, make available to the Secretary of the U.S. Department of Health and Human Services, the Comptroller General of the U.S. Department of Secretary of Health and
Human Services, or any of their fully-authorized representatives, the books, documents, and/or records of such Party that are necessary to verify the nature and extent of costs associated therewith. The record keeping and disclosure provisions of
this Section 7.3 will apply to all services provided, offered or sold a Party hereunder, but will be applicable only if a Party receives remuneration in the amount of $10,000 or more with regard to such services performed in relation to
a single customer. 
  

	8.	Confidentiality. 

 8.1 Obligations. From time to time in connection with
this Agreement, either Party (as the “Disclosing Party”) has or may disclose or make available to the other Party or its Affiliates (each, the “Receiving Party”) Confidential Information, whether before or after the
Effective Date. In such cases, and subject to the exceptions and limitations expressly set forth in this Agreement, the Receiving Party will (a) not use the Disclosing Party’s Confidential Information, or permit it to be accessed or used,
for any purpose other than to exercise its rights or perform its obligations under this Agreement; and (b) not disclose the Disclosing Party’s Confidential Information to any Person except to its Representatives who need to know the
Confidential Information in order to assist the Receiving Party, or to act on its behalf, in exercising the Receiving Party’s rights or performing the Receiving Party’s obligations under this Agreement, where such Representatives are
themselves bound by nondisclosure agreements or obligations as least as restrictive as those set forth in this Section 8.1. The Receiving Party will be responsible for any breach of, or non-compliance with, this Section 8.1
by its Representatives. The obligation not to use or disclose a Party’s Confidential Information will remain in effect until one of the exceptions in Section 8.2 occurs. 

8.2 Exceptions. The restrictions set forth in Section 8.1 will not apply to Confidential Information that, at the time of
disclosure to or receipt by the Receiving Party or its Representatives: (a) is in the public domain or is or becomes generally available to and known by the public other than resulting from, directly or indirectly, any breach of this
Section 8 by the Receiving Party or its Representatives; (b) is or becomes available to the Receiving Party or any of its Representatives on a non-confidential basis from a third party; provided, that such third party is not
and was not prohibited from disclosing the Confidential Information; or (c) was or is independently developed by the Receiving Party or its Representatives without reference to or use of, in whole or in part, any of the Disclosing Party’s
Confidential Information. 
 8.3 Legally Required Disclosure. Notwithstanding anything in this Section 8 to the contrary,
if a Receiving Party or any of its Representatives is required pursuant to applicable Law or the rules or 

  

			
	 Amended and Restated NantOmics Exclusive Reseller Agreement

CONFIDENTIAL
	 	 Page 9 of 20

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
regulations of a stock exchange or similar self-regulatory authority, to disclose any of the Disclosing Party’s Confidential Information, then the Receiving Party agrees, to the extent
legally permissible and as soon as reasonably practicable, to provide the Disclosing Party with written notice of the event so that the Disclosing Party may, at the Disclosing Party’s expense, seek a protective order or other remedy. The
Receiving Party or its Representative (as applicable) will use its commercially reasonable efforts to consult with the Disclosing Party with respect to any effort by the Disclosing Party to resist or narrow the scope of such requirement or request,
or to seek such protective order or other remedy. If such protective order or other remedy is not obtained, then the Receiving Party or its Representative (as applicable): (a) may, without liability, disclose that portion of the Disclosing
Party’s Confidential Information that it is required to disclose; and (b) will use its commercially reasonable efforts to have confidential treatment accorded to the Confidential Information so disclosed. Furthermore, Section 8
will not apply to the disclosure of Confidential Information if such disclosure is necessary to establish rights or enforce obligations under this Agreement, but only to the extent that any such disclosure is necessary. Any information disclosed
pursuant to this Section 8.3 will retain its confidential status for all other purposes. 
 8.4 Effect of Termination.
Upon termination of this Agreement, at the Disclosing Party’s request, the Receiving Party will, and will cause its Representatives (and, if applicable, its Affiliates) to, promptly return or destroy (at the Receiving Party’s option) all
Confidential Information received from the Disclosing Party in tangible form, together with all copies thereof, in such Person’s possession; provided, however, that the Receiving Party may keep one (1) copy of the Disclosing
Party’s Confidential Information: (a) to the extent necessary to exercise its surviving rights and perform its surviving obligations hereunder; (b) to the extent required to be maintained pursuant to applicable law or to satisfy the
Receiving Party’s record retention obligations and (c) in accordance with its corporate security and/or disaster recovery procedures, to the extent such Confidential Information is in electronic form. The Receiving Party will, upon
request, promptly certify in writing that it has complied with the obligations of this Section 8.4. 
 8.5 Protected Health
Information. For the avoidance of doubt, the use and protection of protected health information received by a Party or its Representatives hereunder will be governed by the BAA. 

 

	9.	Public Announcements. 

 9.1 Publicity. Except as may be required by
applicable Law or the rules or regulations of a stock exchange or similar self-regulatory authority, neither Party will issue or release any public announcement, statement, press release or other publicity relating to this Agreement without the
prior written consent of the other Party. 
 9.2 Use of Marks. Except as expressly authorized by this Agreement, neither Party will
use the other Party’s trademarks, service marks, trade names, logos, domain names or other indicia of source, origin, association or sponsorship, without the prior written consent of the other Party. 

 

	10.	Representations and Warranties. 

 10.1 Mutual Representations and
Warranties. Each Party represents and warrants to the other Party that: (a) it is duly formed, validly existing, and in good standing as a limited liability company under the Laws of its jurisdiction of formation; (b) it has, and
throughout the term of this Agreement and any Customer Agreement will retain, the full right, power, and authority to enter into this Agreement, to grant the rights it grants hereunder and to perform its obligations under this Agreement;
(c) its execution of this Agreement has been duly authorized by all necessary organizational action of such Party; (d) when 

  

			
	 Amended and Restated NantOmics Exclusive Reseller Agreement

CONFIDENTIAL
	 	 Page 10 of 20

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
executed and delivered by it, this Agreement will constitute its legal, valid, and binding obligation, enforceable against it in accordance with its terms; and (e) its execution, delivery,
and performance of its obligations under this Agreement does not and will not violate any judgment, order, decree, or applicable Law, nor does it or will it violate any agreement to which it is a party. 

10.2 Disclaimer. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS AGREEMENT, EACH PARTY HEREBY DISCLAIMS ALL WARRANTIES, WHETHER
EXPRESS, IMPLIED, STATUTORY, OR OTHERWISE, WITH RESPECT TO THIS AGREEMENT OR ANY SUBJECT MATTER HEREOF. NEITHER PARTY SHALL MAKE ANY REPRESENTATIONS OR WARRANTIES REGARDING THE OTHER PARTY’S PRODUCTS OR SERVICES OTHER THAN THOSE SET FORTH IN
THIS AGREEMENT. 
  

	11.	Indemnification. 

 11.1 Indemnification. Subject to the provisions of this
Section 11, each Party (the “Indemnifying Party”) agrees to defend the other Party and its Representatives, and all of such Persons’ successors and assigns (collectively, the “Indemnified Persons”),
from and against any and all third party Claims, and indemnify and hold the Indemnified Persons harmless from and against any and all Losses incurred or sustained by the Indemnified Persons, or any of them, to the extent such Claim and related Loss
is a result of any of the following: 
 (a) any violation of applicable Law by the Indemnifying Party; 

(b) any gross negligence or willful misconduct in connection with its performance of any covenant or agreement applicable to Indemnifying
Party contained in this Agreement (including the performance of the Services), including any personal injury, death, or damage to tangible personal or real property; except any of the foregoing based on allegations of medical malpractice or
liability arising out of delivery of (or a failure to deliver) medical care; 
 (c) taxes assessed or claimed against any of the Indemnified
Persons that are obligations of the Indemnifying Party in connection with this Agreement or which result from the breach of this Agreement by the Indemnifying Party; and 

(d) any Claims that the Indemnifying Party’s services, products, marketing materials or any use, promotion, marketing, distribution, sale
or delivery thereof as permitted and in accordance with this Agreement, infringe, misappropriate, or violate any intellectual property or other rights of a third party, including any damages suffered by Indemnified Persons’ customers as a
result thereof for which the Indemnified Persons are liable. 
 11.2 Infringement Remedy. 

(a) In the event of a Claim that the Indemnifying Party’s services, products, or marketing materials, or any use, promotion, marketing,
distribution, sale or delivery thereof in accordance with this Agreement, infringe, misappropriate, or violate any intellectual property right of a third party, or if any use of any of such item (or any respective component thereof) is enjoined or
threatened to be enjoined, then the Indemnifying Party will, at its sole cost and expense, (i) procure for the Indemnified Persons the right to continue to receive and use such item to the full extent contemplated by this Agreement; or
(ii) modify or replace the elements that infringe or are alleged to infringe to make them non-infringing while providing reasonably equivalent services, features and/or functionality (as applicable). 

  

			
	 Amended and Restated NantOmics Exclusive Reseller Agreement

CONFIDENTIAL
	 	 Page 11 of 20

		 	

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 (b) If, in Indemnifying Party’s discretion, none of the options set forth in
Section 11.2(a) are commercially practicable, then either Party will have the right to terminate this Agreement with respect to the applicable products or services immediately. 

(c) The remedies set forth in this Section 11.2 are in addition to, and not in lieu of, all other remedies that may be available
to the Indemnified Persons under this Agreement or otherwise, including the Indemnified Persons’ right to indemnification pursuant to Section 11.1. 

11.3 Exclusions from Indemnification. Notwithstanding Sections 11.1 and 11.2 above, the Indemnifying Party will have no
obligation or liability under this Section 11 for any Claim or action regarding any Claim resulting from any of the following: (a) modifications to the Indemnifying Party’s services, products or marketing materials made
pursuant to the Indemnified Persons’ designs, specifications, or instructions; (b) modifications to the Indemnifying Party’s services, products, or marketing materials by anyone other than the Indemnifying Party, other than
modifications authorized in writing by the Indemnifying Party; (c) the combination, operation, or use of Indemnifying Party’s services, products or marketing materials with other products, processes, or materials if the Indemnifying
Party’s services, products or marketing materials themselves do not infringe; (d) Indemnified Persons’ or its customers’ continued engagement in allegedly infringing activities after receipt of notice from the Indemnifying Party
of a Claim and after being provided with modifications that would have avoided the alleged infringement; or (e) any marketing, sale or use of the Indemnifying Party’s services, products or marketing materials that is not in compliance with
this Agreement. 
 11.4 Indemnification Procedure. 

(a) A Person seeking defense and indemnification under this Section 11 (the “Indemnified Person”) will promptly
notify the Party from whom defense and indemnification is being sought (the “Indemnifying Party”) in writing, describing the circumstances, in reasonable detail, for which it seek defense and indemnification. 

(b) Upon notice of a Claim, the Indemnifying Party will immediately assume the investigation and defense of such Claim, and, in connection
therewith, will employ counsel of its own choosing at its sole cost and expense. At the Indemnifying Party’s request and expense, the Indemnified Person will provide reasonable cooperation in connection with the investigation and defense of
such Claim; provided, however, that the Indemnified Person will not be required to disclose any confidential information which it does not have the right to disclose or to waive any privilege. The Indemnified Person may also
participate in and observe (but not control) the investigation and defense of such Claim, at its own cost and expense and with counsel of its choosing. 

(c) If the Indemnifying Party fails to defend a Claim hereunder within a reasonable amount of time after receiving notice thereof, the
Indemnified Person will have the right, but not the obligation, and without waiving any of its other rights hereunder, to undertake the defense of and to compromise or settle such Claim, on behalf of and at the risk and expense of the Indemnifying
Party. 
 (d) The Indemnifying Party will not settle any Claim in a manner that adversely affects the rights or assets, or restrains or
interferes with the business or operations of, the Indemnified Person or its Affiliates, or which involves an admission of liability of behalf of the Indemnified Person or its Affiliates, or imposes any obligation upon the Indemnified Person that
the Indemnifying Party does not discharge, in each case without the Indemnified Person’s prior written consent (which shall not be unreasonably withheld). 

  

			
	 Amended and Restated NantOmics Exclusive Reseller Agreement

CONFIDENTIAL
	 	 Page 12 of 20

		 	

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 (e) An Indemnified Person’s failure to perform any obligations under this
Section 11.4 will not diminish an Indemnifying Party’s obligations hereunder, except to the extent that the Indemnifying Party can demonstrate that it has been materially prejudiced as a result of such failure. 

 

	12.	Limitation of Liability. 

 12.1 Limitation of Liability. EXCEPT AS
OTHERWISE SET FORTH IN SECTION 12.3, IN NO EVENT WILL A PARTY’S LIABILITY UNDER THIS AGREEMENT EXCEED THE GREATER OF: (i) AGGREGATE FEES AND REIMBURSABLE EXPENSES PAID TO NANTOMICS UNDER THIS AGREEMENT (INCLUDING AMOUNTS ALREADY PAID AND
AMOUNTS THAT HAVE ACCRUED BUT NOT YET BEEN PAID) IN THE EIGHTEEN (18) MONTH PERIOD PRECEDING THE CLAIM AND (ii) ONE MILLION DOLLARS ($1,000,000). 

12.2 EXCLUSION OF CONSEQUENTIAL DAMAGES. EXCEPT AS OTHERWISE SET FORTH IN SECTION 12.3, IN NO EVENT WILL ANY PARTY BE LIABLE
UNDER THIS AGREEMENT FOR ANY LOST PROFITS OR FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY, SPECIAL, OR PUNITIVE DAMAGES, REGARDLESS OF WHETHER SUCH PARTY HAS BEEN NOTIFIED OF THE POTENTIAL FOR SUCH DAMAGES, OR WHETHER SUCH DAMAGES WERE
REASONABLY FORESEEABLE, OR WHETHER ANY CLAIM FOR RECOVERY IS BASED ON THEORIES OF CONTRACT, TORT, OR OTHERWISE. 
 12.3 Exceptions.
The exclusions in Section 12.1 and 12.2 will not apply to (a) Losses arising out of or relating to a Party’s knowing or negligent failure to comply with its obligations under Section 4 (Licenses and Intellectual
Property Ownership) or Section 7 (Regulatory Matters) or failure to comply with Section 8 (Confidentiality); (b) amounts finally awarded by a court of competent jurisdiction to third party claimants which are obligated to be
covered under a Party’s indemnification obligations under Section 11; (c) Losses arising from a Party’s gross negligence or more culpable conduct, including any willful misconduct or intentionally wrongful acts; or (d) a
Party’s obligation to pay attorneys’ fees and other costs pursuant to Section 16.9(e). 
 12.4 Essential Basis. THE
DISCLAIMERS, EXCLUSIONS AND LIMITATIONS OF LIABILITY SET FORTH IN THIS AGREEMENT FORM AN ESSENTIAL BASIS OF THE BARGAIN BETWEEN THE PARTIES AND, ABSENT ANY OF SUCH DISCLAIMERS, EXCLUSIONS OR LIMITATIONS OF LIABILITY, THE PROVISIONS OF THIS
AGREEMENT, INCLUDING THE ECONOMIC TERMS, WOULD BE SUBSTANTIALLY DIFFERENT. THE DISCLAIMERS, EXCLUSIONS AND LIMITATIONS OF LIABILITY SET FORTH IN THIS AGREEMENT WILL APPLY TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, EVEN IF ANY REMEDY FAILS
ITS ESSENTIAL PURPOSE. 
  

	13.	Term. 

 13.1 Initial Term. The initial term of this Agreement commences on
the Effective Date and will continue in effect until December 31, 2020, unless terminated earlier pursuant to Section 14 (the “Initial Term”). The Initial Term, together with each Exclusive Renewal Term (if any) and
the Non-Exclusive Renewal Term (as defined below), are collectively referred to as the “Term”. 
 13.2 Renewal
Options. 
 (a) If NantHealth meets the applicable Renewal Threshold set forth below for the Initial Term, NantHealth may, at its option,
renew this Agreement (with exclusivity under Section 2.2) for an additional three (3) years (i.e., through December 31, 2023) by providing NantOmics with written notice of its election to renew at least ninety (90) days
prior to the end of the Initial Term (the “Initial Exclusive Renewal Term”). 
 (c) Following the Initial Exclusive Renewal
Term, NantHealth may, at its option, renew this Agreement (with exclusivity under Section 2.2) for up to two (2) additional three (3) year periods (i.e., through December 31, 2026 for the first renewal option and through
December 31, 2029 for the second renewal option) (each, an “Additional Exclusive Renewal Term”) by providing NantOmics with written notice at least ninety (90) days prior to the end of the then-current renewal term, if
NantHealth meets the applicable Renewal Threshold for the then-current renewal term. The Initial Exclusive Renewal Term and each Additional Exclusive Renewal Term are collectively referred to as the “Exclusive Renewal Terms.” 

  

			
	 Amended and Restated NantOmics Exclusive Reseller Agreement

CONFIDENTIAL
	 	 Page 13 of 20

		 	

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 (d) The “Renewal Threshold” for the Initial Term and each Exclusive Renewal
Term is set forth in the table below: 
  

			
	 	  	 Renewal Threshold

	Initial Term	  	300,000 Omics Service tests completed between the Effective Date and June 30, 2020
	First Exclusive Renewal Term	  	570,000 Omics Service tests completed between July 1, 2020 and June 30, 2023
	Second Exclusive Renewal Term	  	760,000 Omics Service tests completed between July 1, 2023 and June 30, 2026

 (e) If this Agreement is not renewed for an Exclusive Renewal Term as provided above, then NantHealth may, at
its option at the end of the Initial Term or the first or second Exclusive Renewal Term (as applicable), renew this Agreement on a non-exclusive basis for one additional three (3) year term (the “Non-Exclusive Renewal Term”) by
providing NantOmics with written notice at least ninety (90) days prior to the end of the Initial Term or such Exclusive Renewal Term, in which case the exclusive rights granted to NantHealth under Section 2.2 shall not renew and shall
automatically terminate as of the last day of the Initial Term or such Exclusive Renewal Term. 
 (f) For the avoidance of doubt, this
Agreement shall automatically expire (i) at the end of the Initial Term or the first or second Exclusive Renewal Term, unless renewed by NantHealth as expressly provided above or (ii) in any case, at the end of the third Exclusive Renewal
Term or Non-Exclusive Renewal Term. 
  

	14.	Termination. 

 14.1 Termination for Cause. Either Party may terminate this
Agreement, immediately upon written notice to the other Party, if the other Party materially breaches this Agreement and such breach (a) is incapable of cure or (b) being capable of cure, remains uncured thirty (30) days after the
breaching Party receives written notice from the non-breaching Party thereof. 
 14.2 Termination for Insolvency. Either Party may
terminate this Agreement, immediately upon written notice to the other Party, if the other Party: (a) becomes insolvent or admits inability to pay its debts generally as they become due; (b) becomes subject, voluntarily or involuntarily,
to any proceeding under any domestic or foreign bankruptcy or insolvency Law, which is not fully stayed within seven (7) days or is not dismissed or vacated within forty-five (45) days after filing; (c) is dissolved or liquidated or
takes any action for such purpose; (d) makes a general assignment for the benefit of creditors; or (e) has a receiver, trustee, custodian, or similar agent appointed by order of any court of competent jurisdiction to take charge of or sell
any portion of its property or business (and such appointment is not discontinued within sixty (60) days thereafter). 
 14.3
Termination for Force Majeure. Subject to Section 6.2, either Party may terminate this Agreement, immediately upon written notice to the other Party, if a Force Majeure Event affecting the other Party continues substantially
uninterrupted for a period of thirty (30) days or more. 

  

			
	 Amended and Restated NantOmics Exclusive Reseller Agreement

CONFIDENTIAL
	 	 Page 14 of 20

		 	

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 14.4 Termination for Exclusion. Either Party may terminate this Agreement, immediately
upon written notice to the other Party, if the other Party is debarred, excluded, suspended or otherwise determined to be ineligible to participate in federal healthcare programs (collectively, “Excluded” or
“Exclusion”). Accordingly, the Excluded Party will provide the other Party with prompt written notice if it (a) receives notice of action or threat of action with respect to its Exclusion during the term of this Agreement; or
(b) becomes Excluded. 
 14.5 Termination for Convenience. NantHealth may terminate this Agreement at any time for any reason
upon providing at least six (6) months prior written notice to NantOmics. 
 14.6 Effect of Termination. 

(a) The termination of this Agreement will not have the effect of terminating any Customer Agreement entered into prior to the effective date
of termination. Each Party will continue to honor commitments made under the terms and conditions of each such Customer Agreement for up to three (3) years after the effective date of termination of this Agreement, including the provision of
Services to/for such Institutional Customers for such three (3) year period. NantHealth will continue to make payments to NantOmics with respect to each Customer Agreement still in effect in accordance with this Agreement. 

(b) Upon termination of this Agreement, except in connection with the rights and obligations set forth in this Section 14.6,
(i) NantHealth shall promptly cease all use of the NantOmic’s Marks and all marketing and sales-related efforts with respect to the Omics Services; (ii) NantHealth will promptly cease to solicit or procure orders/transactions for
Omics Services; (iii) NantHealth shall promptly deliver a copy of all Omics Data in its possession and return to NantOmics all copies of NantOmic’s marketing and related materials; (iv) NantHealth shall promptly discontinue its use of
Omics Data and delete and otherwise remove or destroy all other copies of any Omics Data that is in NantHealth’s possession or control; and (v) each Party will provide reasonable cooperation and assistance to the other Party in
transitioning Institutional Customers to NantOmics for the continued provision of Omics Services. 
 15. Survival. The provisions of
Sections 1 (Definitions), 3.3 (Expenses), 3.4 (Taxes), 3.5 (Records and Audits), 4.5 (Restrictions), 4.6 (Ownership, Reservation of Rights), 6 (Force Majeure), 8 (Confidentiality), 10.2
(Disclaimer), 11 (Indemnification), 12 (Limitation of Liability), 14.6 (Effect of Termination), 15 (Survival), and 16 (Miscellaneous) will survive and continue after expiration or termination of this Agreement
indefinitely. The provisions of Sections 2.3 (Customer Engagement, Billing and Order Processing) through 2.11 (Other Services), 3.1 (Revenue Share), 5 (Other Covenants), 7 (Regulatory Matters) and 10.1
(Mutual Representations and Warranties) will survive and continue after termination of this Agreement for the full duration of any Customer Agreement, but in each case solely with respect to any such continuing Customer Agreement. In addition, the
rights and obligations of any Party which, by their nature, extend beyond the termination of this Agreement will continue in full force and effect notwithstanding the termination of this Agreement. 

 

	16.	Miscellaneous. 

 16.1 Relationship of the Parties. The relationship between
the Parties is that of independent contractors. Nothing contained in this Agreement will be construed as creating any agency, partnership, joint venture, or other form of joint enterprise, employment, or fiduciary relationship between the Parties.
Neither Party will have authority to contract for or bind the other Party in any manner whatsoever, except as expressly set forth in this Agreement. 

  

			
	 Amended and Restated NantOmics Exclusive Reseller Agreement

CONFIDENTIAL
	 	 Page 15 of 20

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 16.2 Notices. All notices hereunder will be in writing and addressed to a Party at the
address set forth under such Party’s name on the signature page hereto (or as otherwise specified by a Party in a notice given in accordance with this Section 16.2). Notices sent in accordance with this Section 16.2 will
be deemed effectively given: (a) when received, if delivered by hand (with written confirmation of receipt); (b) when received, if sent by a nationally recognized overnight courier (receipt requested); or (c) on the third (3rd) day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. 

16.3 Interpretation. For purposes of this Agreement, (a) the words “include,” “includes,” and
“including” will be deemed to be followed by the words “without limitation”; (b) the word “or” is not exclusive; and (c) the words “herein,” “hereof,” “hereby,”
“hereto,” and “hereunder” refer to this Agreement as a whole. Unless the context otherwise requires, references herein: (i) to Sections and Exhibits refer to the sections of, and exhibits attached to, this Agreement;
(ii) to an agreement, instrument, or other document means such agreement, instrument, or other document as amended, supplemented, and modified from time to time to the extent permitted by the provisions thereof; and (iii) to a statute
means such statute as amended from time to time and includes any successor legislation thereto and any regulations promulgated thereunder. This Agreement will be construed without regard to any presumption or rule requiring construction or
interpretation against the Party drafting an instrument or causing an instrument to be drafted. The Exhibits referred to herein will be construed with, and as an integral part of, this Agreement to the same extent as if they were set forth verbatim
herein. The headings in this Agreement are for reference only and will not affect the interpretation of this Agreement. 
 16.4
Assignment. Neither Party may assign or otherwise transfer any of its rights, or delegate or otherwise transfer any of its obligations or performance, under this Agreement, in each case whether voluntarily or involuntarily, without the other
Party’s prior written consent, which will not be unreasonably withheld, conditioned, or delayed; provided, however, that NantOmics may assign this Agreement to an Affiliate with the capability to provide and perform the NantOmics Services or in
connection with the sale of all or substantially all of the assets to which this Agreement relates. Any assignment, delegation, or other transfer without such prior written consent will be null and void. This Agreement is binding upon and inures to
the benefit of the Parties and their respective permitted successors and assigns. 
 16.5 No Third Party Beneficiaries. This
Agreement is for the sole benefit of the Parties, their respective permitted successors and assigns, and the Indemnified Persons, and nothing herein, express or implied, is intended to or will confer on any other Person any legal or equitable right,
benefit, or remedy of any nature whatsoever under or by reason of this Agreement. 
 16.6 Amendment and Modification; Waiver. This
Agreement may only be amended, modified or supplemented by an agreement in writing signed by each Party. No waiver by any Party of any of the provisions hereof will be effective unless explicitly set forth in writing and signed by the Party so
waiving. Except as otherwise set forth in this Agreement, no failure to exercise, or delay in exercising, any right, remedy, power or privilege arising from this Agreement will operate or be construed as a waiver thereof; nor will any single or
partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. 

16.7 Severability. If any provision of this Agreement or the application thereof to any Party or circumstances is declared void,
illegal, or unenforceable, then the remainder of this Agreement will be valid and enforceable to the extent permitted by applicable Law. 

  

			
	 Amended and Restated NantOmics Exclusive Reseller Agreement

CONFIDENTIAL
	 	 Page 16 of 20

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 16.8 Governing Law. This Agreement will be governed by and construed in accordance
with the Laws of the State of California applicable to agreements made and to be performed wholly within that State without regard to its conflicts of laws provisions. 

16.9 Dispute Resolution. 

(a) Informal Resolution. Except as otherwise provided in this Agreement, in the event of any dispute, claim, or controversy arising
under, out of, or in connection with this Agreement (a “Dispute”), including as to the breach, performance, or interpretation of this Agreement or the rights, duties or liabilities of either Party hereunder, the Parties will first
attempt in good faith to resolve such Dispute by negotiation and consultation between themselves. If such Dispute is not resolved on an informal basis within thirty (30) days, each Party may, at its sole discretion, seek resolution of such
matter in accordance with Section 16.9 and exercise its rights according to any other applicable sections of this Agreement, including, but not limited to, Section 14. 

(b) Arbitration. Except as otherwise expressly provided in this Section, if the Parties do not reach a mutually acceptable resolution
pursuant to Section 16.9(a) as to a Dispute, the Dispute shall be referred for resolution by final, binding arbitration in accordance with the provisions of this Section. The arbitration shall be conducted by the American Arbitration
Association (or any successor entity thereto) (“AAA”) under its rules of commercial arbitration then in effect, except as modified in this Agreement. The arbitration shall be conducted in the English language, by a single arbitrator
knowledgeable in the subject matter at issue in the Dispute and acceptable to both Parties; provided, however, that the Parties may by mutual agreement elect to have the arbitration conducted by a panel of three arbitrators (such single arbitrator
or panel, the “Arbitrator”). The Arbitrator shall, if appropriate, engage an independent expert with experience in the subject matter of the Dispute to advise the Arbitrator. 

(i) With respect to any Dispute referred to arbitration pursuant to this Section 16.9, the Parties and the
Arbitrator shall use all reasonable efforts to complete any such arbitration within three (3) months from the issuance of notice of a referral of any such Dispute to arbitration. The Arbitrator shall determine what discovery will be permitted,
consistent with the goal of limiting the cost and time which the Parties must expend for discovery; provided that the Arbitrator shall permit such discovery as he or she deems necessary to permit an equitable resolution of the Dispute. 

(ii) The decision of the Arbitrator shall be the sole, exclusive, and binding remedy between them regarding the Dispute
presented to the Arbitrator. Any decision of the Arbitrator may be entered in a court of competent jurisdiction for judicial recognition of the decision and an order of enforcement. The arbitration proceedings and the decision of the Arbitrator
shall not be made public without the joint consent of the Parties, and each Party shall maintain the confidentiality of such proceedings and decision. 

(iii) Unless otherwise agreed by the Parties, the arbitration proceedings shall be conducted in Los Angeles, California. The
Parties shall share equally the cost of the arbitration filing and hearing fees, the cost of the independent expert retained by the Arbitrator, and the cost of the Arbitrator and administrative fees of AAA. Each Party shall bear its own costs and
attorneys’ and witnesses’ fees and associated costs and expenses. 
 (c) Temporary Relief. Pending the selection of the
Arbitrator or pending the Arbitrator’s determination of the merits of any Dispute, either Party may seek appropriate interim or provisional relief from any court of competent jurisdiction as necessary to protect the rights or property of that
Party. 

  

			
	 Amended and Restated NantOmics Exclusive Reseller Agreement

CONFIDENTIAL
	 	 Page 17 of 20

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 16.10 Waiver of Jury Trial. EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY
CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT OR THE SUBJECT MATTER HEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT
MATTER OF THIS AGREEMENT, INCLUDING CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. 

16.11 Equitable Relief. Notwithstanding anything else in this Agreement to the contrary, each Party acknowledges that a breach by a
Party of this Agreement may cause the non-breaching Party immediate and irreparable harm, for which an award of damages may not be adequate compensation and agrees that, in the event of such breach or threatened breach, the non-breaching Party will
be entitled to seek equitable relief, including in the form of orders for preliminary or permanent injunction, specific performance, interim or conservatory relief, and any other relief that may be available for any court, and the Parties hereby
waive any requirement for the securing or posting of any bond in connection with such relief. Such remedies will not be deemed to be exclusive but will be in addition to all other remedies available under this Agreement, at law or in equity, subject
to any express exclusions or limitations in this Agreement to the contrary. 
 16.12 Counterparts. This Agreement may be executed in
counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. Counterparts may be delivered by facsimile, electronic mail (including .pdf or any electronic signature complying with the
U.S. Federal ESIGN Act of 2000) or other transmission method, and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

16.13 Entire Agreement. This Agreement, together with all Exhibits and the BAA, constitutes the sole and entire agreement between the
Parties solely with respect to the subject matter hereof, and supersedes all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter. There are no agreements, representations, warranties,
covenants or undertakings with respect to the subject matter hereof other than those expressly set forth herein. 
 [Signature Page Follows]

  

			
	 Amended and Restated NantOmics Exclusive Reseller Agreement

CONFIDENTIAL
	 	 Page 18 of 20

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated NantOmics Exclusive Reseller
Agreement as of the date first written above. 
  

									
	NantOmics, LLC	  		  	Nant Health, LLC
					
	By:	  	 /s/ Charles Kim 
	  		  	By:	  	 /s/ Robert Watson

	Name:	  	Charles Kim	  		  	Name:	  	Robert Watson
	Title:	  	General Counsel	  		  	Title:	  	President
			
	Address for Notices:	  		  	Address for Notices:
			
	9920 Jefferson Blvd.	  		  	9920 Jefferson Blvd.
	Culver City, CA 90232	  		  	Culver City, CA 90232
	Attention: General Counsel	  		  	Attention: President

  

			
	 Amended and Restated NantOmics Exclusive Reseller Agreement

CONFIDENTIAL
	 	 Page 19 of 20

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL
IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 EXHIBIT A 

LICENSE AGREEMENT 

Attached 

  

			
	 Amended and Restated NantOmics Exclusive Reseller Agreement

CONFIDENTIAL
	 	 Page 20 of 20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}]]